CryoLife Upgraded to Outperform by Zacks (CRY)
CryoLife (NYSE:CRY) was upgraded by Zacks from a “neutral” rating to an “outperform” rating in a note issued to investors on Wednesday, AnalystRatingsNetwork.com reports. The firm currently has a $9.40 price target on the stock. Zacks‘ price target would suggest a potential downside of 0.63% from the company’s current price.
CryoLife (NYSE:CRY) traded up 5.23% on Wednesday, hitting $9.46. 205,114 shares of the company’s stock traded hands. CryoLife has a one year low of $5.52 and a one year high of $9.49. The stock’s 50-day moving average is $7.45 and its 200-day moving average is $6.70. The company has a market cap of $261.3 million and a P/E ratio of 33.30.
CryoLife (NYSE:CRY) last issued its quarterly earnings data on Tuesday, October 29th. The company reported $0.12 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.05 by $0.07. The company had revenue of $36.30 million for the quarter, compared to the consensus estimate of $35.51 million. During the same quarter in the prior year, the company posted $0.08 earnings per share. The company’s quarterly revenue was up 8.7% on a year-over-year basis. Analysts expect that CryoLife will post $0.60 EPS for the current fiscal year.
CryoLife, Inc (NYSE:CRY) is a biological medical device company.
To view Zacks’ full report, visit www.zacks.com
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.